Your browser doesn't support javascript.
loading
Activation of sirtuin 1 as therapy for the peroxisomal disease adrenoleukodystrophy.
Morató, L; Ruiz, M; Boada, J; Calingasan, N Y; Galino, J; Guilera, C; Jové, M; Naudí, A; Ferrer, I; Pamplona, R; Serrano, M; Portero-Otín, M; Beal, M F; Fourcade, S; Pujol, A.
Afiliação
  • Morató L; Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
  • Ruiz M; Center for Biomedical Research on Rare Diseases (CIBERER) ISCIII, Spain.
  • Boada J; Institute of Neuropathology, University of Barcelona, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
  • Calingasan NY; Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
  • Galino J; Center for Biomedical Research on Rare Diseases (CIBERER) ISCIII, Spain.
  • Guilera C; Institute of Neuropathology, University of Barcelona, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
  • Jové M; Experimental Medicine Department, University of Lleida-IRBLleida, 25008 Lleida, Spain.
  • Naudí A; Department of Neurology and Neuroscience, Weill Cornell Medical College, 1006 New York, USA.
  • Ferrer I; Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
  • Pamplona R; Center for Biomedical Research on Rare Diseases (CIBERER) ISCIII, Spain.
  • Serrano M; Institute of Neuropathology, University of Barcelona, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
  • Portero-Otín M; Neurometabolic Diseases Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
  • Beal MF; Center for Biomedical Research on Rare Diseases (CIBERER) ISCIII, Spain.
  • Fourcade S; Institute of Neuropathology, University of Barcelona, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.
  • Pujol A; Experimental Medicine Department, University of Lleida-IRBLleida, 25008 Lleida, Spain.
Cell Death Differ ; 22(11): 1742-53, 2015 Nov.
Article em En | MEDLINE | ID: mdl-25822341
ABSTRACT
Oxidative stress and mitochondrial failure are prominent factors in the axonal degeneration process. In this study, we demonstrate that sirtuin 1 (SIRT1), a key regulator of the mitochondrial function, is impaired in the axonopathy and peroxisomal disease X-linked adrenoleukodystrophy (X-ALD). We have restored SIRT1 activity using a dual strategy of resveratrol treatment or by the moderate transgenic overexpression of SIRT1 in a X-ALD mouse model. Both strategies normalized redox homeostasis, mitochondrial respiration, bioenergetic failure, axonal degeneration and associated locomotor disabilities in the X-ALD mice. These results indicate that the reactivation of SIRT1 may be a valuable strategy to treat X-ALD and other axonopathies in which the control of redox and energetic homeostasis is impaired.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Estilbenos / Adrenoleucodistrofia / Sirtuína 1 Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Estilbenos / Adrenoleucodistrofia / Sirtuína 1 Idioma: En Ano de publicação: 2015 Tipo de documento: Article